22% of the antibody drugs withdrawn from the market, often due to safety issues, showed nonspecific binding. 33% of the 254 lead molecules tested showed nonspecific binding, a predictor of failure in future stages of development. These findings challenge the long-held belief in the absolute spec...
Lexchin, JoelSimonyan, DavidSpringer International PublishingPharmaceutical MedicineLa Rochelle P, Lexchin J, Simonyan D. Analysis of the drugs withdrawn from the US market from 1976 to 2010 for safety reasons. Pharmaceut Med 2016; 30:277-89....
Bextra was withdrawn from the U.S. market in 2005.The manufacturer of Bextra has announced the voluntary withdrawal of the drug from the U.S. market. This withdrawal is due to safety concerns of an increased risk of cardiovascular events (including heart attack and stroke) in patients taking...
However, Belviq was withdrawn from the market in 2020 due to safety concerns over a risk of cancer.Qsymia is used for weight control in:Adults: Those who are obese (BMI of 30 kg/m2 or higher) OR those who are overweight (BMI of at least 27 kg/m2) and also have at least one ...
A total of 1318 drugs (1291 FDA-approved drugs plus 27 withdrawn drugs) were classified into four groups depending on their DICT potentials: Most-, Less-, Ambiguous-, and No-DICT-Concern. The Most-DICT-Concern group contained drugs withdrawn from the market due to severe DICT, drugs with ...
Withdrawn Drugs: Drugs that have been withdrawn from the market due to safety concerns but are still in circulation due to various reasons, such as recalls or inadequate communication to healthcare providers and patients. Off-Label Use: When drugs are prescribed for uses not approved by regulatory...
management, due to the discovery of long-term use of Kayseri celecoxib and rofecoxib may increase cardiovascular adverse events, so the two drugs have been withdrawn from the market. 3. naphthalene (nabumetone) is a precursor drug, listed in 1985. ...
Approved drugsAprotinin was approved by the FDA and EMA to reduce blood loss during bypass surgery. After being temporarily withdrawn from the market by the manufacturer in 2008, due to serious adverse events, it is now being reapproved for use in high-risk patients [87,88,89,90,91,92]. ...
Cisapride, a prokinetic drug used for gastrointestinal motility disorders, was withdrawn from the human market in 2000 due to safety concerns. However, cisapride is a valuable prokinetic option for veterinary patients, especially for cats with colonic motility disorders. Currently, veterinarians must ...
In 1950s, phenformin, buformin and metformin were synthesized and later approved for diabetes treatments; however, due to an increased risk of lactic acidosis, the first two were withdrawn from the market in the 1970s [240]. Metformin, though, has established its role and is now likely th...